05.21.24
A hyaluronic acid matrix ingredient marketed by Bioiberica as Dermial recently was investigated in a debut clinical trial evaluating its efficacy in supporting skin health, in a clinical study pending publication.
The company reported that, based on the results, Dermial can reduce wrinkles while supporting skin hydration and a ‘glow’ effect, at a daily dose of 60 mg. The company presented the findings at the Annual Meeting of the Society for Investigative Dermatology (SID) in Dallas, as well as at Vitafoods Europe in Geneva.
Dermial contains a high potency of hyaluronic acid (60-75%) in addition to other beneficial constituents like sulfated glycosaminoglycans and collagen, which work synergistically with hyaluronic acid. Previous in vitro research has supported the potential role of Dermial in improving the health, nutrition, and moisturization of skin.
In the present study, 60 women between ages 35 and 65 were randomized to take either a 60 mg Dermial supplement or a matching placebo for 12 weeks. Researchers took measurements of skin brightness, finding that measurements of skin brightness improved by 20% at week six and by 34% at week 12, with statistically significant differences between both arms occurring at week six.
Significant improvements were also observed in hydration of the stratum corneum (the outermost layer of the epidermis), scaliness, skin temperature, and erythema index (redness of the skin), compared to baseline at six weeks.
“Taken together, these results confirm that a low daily dose of Dermial is safe and supports the homeostasis, appearance, and integrity of aging skin,” said Daniel Martinez-Puig, head of R&D for human and animal health at Bioiberica. “We also assessed satisfaction scores in both groups. Consumer satisfaction was significantly higher in supplemented women (69%) compared to placebo (42%), indicating they experienced tangible benefits when using Dermial.
“This is an exciting time for innovation in the nutricosmetics space,” said Antonio Vendrell, marketing director at Bioiberica. “There is ever-growing demand for beauty-from-within solutions, from consumers of all demographics and backgrounds, and the market craves science-backed and convenient solutions. We’re therefore extremely excited to share this latest compelling evidence from our clinical trial and soaring consumer satisfaction scores, as it gives our partners confidence that, once they’ve experienced Dermial, consumers will be back for more.”
The company reported that, based on the results, Dermial can reduce wrinkles while supporting skin hydration and a ‘glow’ effect, at a daily dose of 60 mg. The company presented the findings at the Annual Meeting of the Society for Investigative Dermatology (SID) in Dallas, as well as at Vitafoods Europe in Geneva.
Dermial contains a high potency of hyaluronic acid (60-75%) in addition to other beneficial constituents like sulfated glycosaminoglycans and collagen, which work synergistically with hyaluronic acid. Previous in vitro research has supported the potential role of Dermial in improving the health, nutrition, and moisturization of skin.
In the present study, 60 women between ages 35 and 65 were randomized to take either a 60 mg Dermial supplement or a matching placebo for 12 weeks. Researchers took measurements of skin brightness, finding that measurements of skin brightness improved by 20% at week six and by 34% at week 12, with statistically significant differences between both arms occurring at week six.
Significant improvements were also observed in hydration of the stratum corneum (the outermost layer of the epidermis), scaliness, skin temperature, and erythema index (redness of the skin), compared to baseline at six weeks.
“Taken together, these results confirm that a low daily dose of Dermial is safe and supports the homeostasis, appearance, and integrity of aging skin,” said Daniel Martinez-Puig, head of R&D for human and animal health at Bioiberica. “We also assessed satisfaction scores in both groups. Consumer satisfaction was significantly higher in supplemented women (69%) compared to placebo (42%), indicating they experienced tangible benefits when using Dermial.
“This is an exciting time for innovation in the nutricosmetics space,” said Antonio Vendrell, marketing director at Bioiberica. “There is ever-growing demand for beauty-from-within solutions, from consumers of all demographics and backgrounds, and the market craves science-backed and convenient solutions. We’re therefore extremely excited to share this latest compelling evidence from our clinical trial and soaring consumer satisfaction scores, as it gives our partners confidence that, once they’ve experienced Dermial, consumers will be back for more.”
